New data show strong overall survival rates, building on previously reported outcomes with efti plus pembrolizumab for head ...

The FDA has approved a ready-to-dilute, multi-dose formulation of thiotepa (Tepylute) for use in breast and ovarian ...

The selective CDK2 inhibitor INX-315 has been given FDA fast track designation for use in CCNE1-amplified, platinum-resistant ...

The subcutaneous formulation of daratumumab makes treatment a faster and more tolerable process for patients with multiple ...

Final data from the phase 3 ALCYONE trial support frontline use of daratumumab-based therapy for patients with ...

For combination therapy, the FDA recommends 200 mg of penpulimab-kcqx every 3 weeks. Monotherapy is recommended at 200 mg ...

Both those receiving either expected or less-than-expected starting dosages of ruxolitinib for myelofibrosis treatment ...

The FDA has approved a ready-to-dilute, multi-dose formulation of thiotepa (Tepylute) for use in breast and ovarian ...

AYA Cancer Awareness month offers an opportunity for nurses to go further in supporting AYAs with cancer.

Nurse practitioners and physician assistants can advocate to play a number of roles in oncology research, including primary ...

The PFS benefit with T-DXd was observed across all prespecified patient subgroups. Overall survival (OS) data were not mature ...

Despite the COVID-19 pandemic and related health care disruptions that caused a decrease in cancer incidence, overall cancer ...